Takeda Pharmaceutical Co. Ltd. · TSE:4502
Takeda Pharmaceutical — Q2 2023 Earnings Presentation
61 slides from Takeda Pharmaceutical's earnings presentation, Oct 26, 2023
Slide 1: Committed to Growth & Shareholder Returns
TSE: 4502 Committed to Growth & Shareholder Returns FY2023 Q2 Earnings Announcement October 26th, 2023
Slide 2: Important Notice
Important Notice For the purposes of this notice, “presentation” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this presentation. This presentation (i
Slide 3: Agenda
Introduction Christophe Weber President & CEO Pipeline Update Andy Plump President, R&D AGENDA Financials Costa Saroukos Chief Financial Officer Q&A Session
Slide 4: Better Health for People, Brighter Future for the World
Better Health for People, Brighter Future for the World Our vision is to discover and deliver life-transforming treatments, guided by our commitment to: We are guided by our values of Takeda-ism which incorporate Integrity, Fairness, Honesty, and PATIENT PEOPLE PLANET • Responsibly translate • Accel
Slide 5: FY2023 H1 Results: Steady Progress Towards Management Guidance
FY2023 H1 Results: Steady Progress Towards Management Guidance; Non-Cash Impairment of Intangible Assets Impacting Reported Profit Topline Driven by Growth & Launch Products No Change to Full-Year Management Guidance • H1 revenue growth +1.4% at CER1 driven by • Reported forecasts updated to reflect
Slide 6: FY2023 Q2 Business Updates: Executing Strategy for Long-Term Growth
FY2023 Q2 Business Updates: Executing Strategy for Long-Term Growth Maximizing Value of Existing Portfolio Driving Progress in Innovative Pipeline • Subcutaneous (SC) administration approved by • TAK-721 resubmitted to U.S. FDA for treatment of U.S. FDA in ulcerative colitis1; submission under Eosin
Slide 7: ENTYVIO Pen Launch is a Significant Milestone to Drive Further Growth
ENTYVIO Pen Launch is a Significant Milestone to Drive Further Growth Maintaining #1 Market Position Continued Growth Outlook Fueled by Targeted Investments ENTYVIO maintains the lead as #1 in IBD overall and IBD bio-naïve Near-term focus on Entyvio Pen subcutaneous (SC) opportunity in U.S. new star
Slide 8: Positive Momentum for QDENGA in Endemic and Travel Markets
Positive Momentum for QDENGA in Endemic and Travel Markets; Recommended by WHO’s Strategic Advisory Group of Experts (SAGE) Positive Uptake in Endemic Market Private Sectors; SAGE Recommendation Could Accelerate Strong Launch in Travel Markets Led by the EU Public Vaccination Program Decisions • End
Slide 9: Committed to Growth & Shareholder Returns
Committed to Growth & Shareholder Returns Near-term Medium-term Long-term (FY2024-2025) (FY2026 - early 2030s) (FY2030s and beyond) Return to sales, profit & margin growth Continued expansion of Growth & Launch Products Further launches from innovative late-stage pipeline Limited Loss of Exclusivity
Slide 10: Agenda
Introduction Christophe Weber President & CEO Pipeline Update Andy Plump President, R&D AGENDA Financials Costa Saroukos Chief Financial Officer Q&A Session
Slide 11: Major Updates to Our Pipeline Since Q1 FY23
Major Updates to Our Pipeline Since Q1 FY23 • Positive Phase 2b study for the treatment of Active Psoriatic Arthritis to be presented at the American College of Rheumatology in November TAK-279 • Target Phase 3 study start in Psoriasis FY23 PIPELINE • Target Phase 3 study start in Psoriatic Arthriti
Slide 12: Promising Late-stage Development Programs with Upcoming Inflections
Promising Late-stage Development Programs with Upcoming Inflections FY23 FY24 FY25-27 Psoriasis Psoriasis Ph3 Start1 Target Filling Psoriatic Arthritis Psoriatic Arthritis TAK-279 Ph2b Readout Ph3 Start GASTROINTESTINAL Crohn’s Disease, Ulcerative Colitis, SLE, Others AND INFLAMMATION Ph2b Start TAK
Slide 13: TAK-721: Potential First Oral Treatment Option for Eosinophilic Esophagitis
TAK-721: Potential First Oral Treatment Option for Eosinophilic Esophagitis (EoE) Eosinophilic Esophagitis Co-Primary Endpoints of Pivotal Trial2 Histologic Response at 12 Weeks Symptom Response at 12 Weeks • Rare, inflammatory disease of the esophagus, often (peak ≤ 6 eosinophils/hpf on biopsy) (≥
Slide 14: Data-driven Decisions Will Further Inform Mid-stage Pipeline Development
Data-driven Decisions Will Further Inform Mid-stage Pipeline Development FY23 FY24 GASTROINTESTINAL TAK-227 Celiac disease AND INFLAMMATION Narcolepsy TAK-861 (NT1 and NT2) NEUROSCIENCE danavorexton Postanesthesia Recovery Postanesthesia Recovery (TAK-925) Ph1 data presented at IARS subasumstat Soli
Slide 15: FY2023: Multiple Potential Approvals for NMEs and Indication Expansions
FY2023: Multiple Potential Approvals for NMEs and Indication Expansions UC U.S. approval ENTYVIO SC CD Japan approval U.S. approval1 QDENGA Dengue vaccine Endemic countries2 TAK-755 cTTP U.S. approval fruquintinib mCRC U.S. approval KEY POTENTIAL REGULATORY TAK-721 Eosinophilic esophagitis U.S. appr
Slide 16: Agenda
Introduction Christophe Weber President & CEO Pipeline Update Andy Plump President, R&D AGENDA Financials Costa Saroukos Chief Financial Officer Q&A Session
Slide 17: FY2023 H1 Results: Steady Progress Towards Management Guidance
FY2023 H1 Results: Steady Progress Towards Management Guidance; Non-Cash Impairment of Intangible Assets Impacting Reported Profit FY2023 H1 (APR -SEP) • Revenue JPY 2,101.7B (USD 14.1B)1 grew +1.4% at CER2, or +6.4% at actual exchange rates TOPLINE • Growth & Launch Products +12.7% at CER, represen
Slide 18: Growth & Launch Products Driving H1 Revenue Growth of +1.4% at CER
Growth & Launch Products Driving H1 Revenue Growth of +1.4% at CER; Reported Operating & Net Profit Impacted by Large Non-Core Items in Q2 FY2023 H1 (APR-SEP) FINANCIAL RESULTS (SUMMARY) (BN YEN, except EPS) REPORTED CORE1 FY2023 H1 ACTUAL % CHANGE FY2023 H1 ACTUAL % CHANGE CER % CHANGE2 REVENUE 2,1
Slide 19: Growth & Launch Products +13% at CER; Represent 42% of Total Revenue
Growth & Launch Products +13% at CER; Represent 42% of Total Revenue FY2023 H1 REVENUE PLASMA-DERIVED THERAPIES (PDT) GI RARE DISEASES IMMUNOLOGY ONCOLOGY NEUROSCIENCE OTHER % of Sales: 28% % of Sales: 18% % of Sales: 18% % of Sales: 11% % of Sales: 16% % of Sales: 9% Growth: +3% Growth: +2% Growth:
Slide 20: Delivered H1 Topline Growth of +1.4% as Growth & Launch Products Offset LOE
Delivered H1 Topline Growth of +1.4% as Growth & Launch Products More Than Offset Impact of LOE and Lower Coronavirus Vaccines Revenue FY2023 H1 REVENUE VS PRIOR YEAR (BN JPY) +6.4% 2,101.7 +1.4% at CER 98.7 -65.9 1,974.8 Includes VYVANSE, AZILVA, VELCADE and DEXILANT FY2022 H1 Growth & LOE impacted
Slide 21: Core Operating Profit Impacted by LOE of Higher Margin Products
Core Operating Profit Impacted by LOE of Higher Margin Products, Decline in Coronavirus Vaccines Revenue, and Investment in R&D and Data & Technology FY2023 H1 CORE OPERATING PROFIT VS PRIOR YEAR (BN JPY) -5.8% -9.5% at CER 625.2 588.8 22.8 FY2022 H1 Core Growth & Launch LOE impacted products Invest
Slide 22: Reported Operating Profit Impacted by Large Non-Core Items in Q2
Reported Operating Profit Impacted by Large Non-Core Items in Q2 FY2023 H1 REPORTED OPERATING PROFIT VS PRIOR YEAR (BN JPY) -53.2% 255.0 Reflects JPY 115.8B impairment of intangible assets booked in FY2023 H1, mainly related to ALOFISEL and EXKIVITY Includes higher restructuring costs and additional
Slide 23: FY2023 Forecasts Reflect Updated FX Assumptions; No Change to Management Guidance
FY2023 Forecasts Reflect Updated FX Assumptions and Non-Core Items in Q2; No Change to Management Guidance • Management Guidance reflects significant loss of exclusivity impact and lower coronavirus vaccines revenue, and investment in R&D and Data & Technology to secure long-term competitiveness • C
Slide 24: FY2023 H1 Results: Steady Progress Towards Management Guidance
FY2023 H1 Results: Steady Progress Towards Management Guidance; Non-Cash Impairment of Intangible Assets Impacting Reported Profit FY2023 H1 (APR -SEP) • Revenue JPY 2,101.7B (USD 14.1B)1 grew +1.4% at CER2, or +6.4% at actual exchange rates TOPLINE • Growth & Launch Products +12.7% at CER, represen
Slide 25: Upcoming Takeda Investor Events
Upcoming Takeda Investor Events PLASMA-DERIVED THERAPIES DECEMBER 5TH, 2023 TUESDAY (6pm ET start) INVESTOR CALL DECEMBER 6TH, 2023 WEDNESDAY (8am JST start) FY2023 Q3 EARNINGS FEBRUARY 1ST, 2024 THURSDAY CONFERENCE CALL (TIME TO BE CONFIRMED) 25
Slide 26: Q&A Session
Q&A SESSION C H RI S T O PH E WE BE R A N D Y PL U MP C O S T A S A RO U K O S Representative Director; Director; President, Director; President & CEO Research & Development Chief Financial Officer RA MO N A S E Q U E IRA J U L IE K IM MI L A N O FU RU T A President, President, President, Japan Glob
Slide 27: Appendix
APPENDIX
Slide 28: Continued Debt Reduction with $1B Payment of Bond Maturing in Q2
Continued Debt Reduction with $1B Payment of Bond Maturing in Q2; 100% of Outstanding Debt at Fixed Rates with ~2% Weighted Average Interest MATURITY LADDER AS OF 30 SEPTEMBER 2023 1,000 800 600 BILLION JPY 400 HYBRID 200 PAID IN FY23 Q2 - ‖ ‖ ‖ ‖ ‖ FY 23 FY 24 FY 25 FY 26 FY 27 FY 28 FY 29 FY 30 FY
Slide 29: ENTYVIO Growth Continues to Drive Expansion of GI Franchise
G AST R OENT ER OL OG Y ( G I) ENTYVIO Growth Continues to Drive Expansion of GI Franchise Despite DEXILANT Loss of Exclusivity Headwind GI PORTFOLIO FY2023 H1 Revenue JPY 391.7B (+5.8% growth) FY 2023 H 1 R E V E N UE • FY23 H1 net sales were +5.8% reflecting single-digit market growth, impact of s
Slide 30: TAKHZYRO Continues its Strong Growth; LIVTENCITY Market Penetration
R AR E D ISEASES TAKHZYRO Continues its Strong Growth with New Patient Reach LIVTENCITY Strong Market Penetration in U.S. & Rapid Geographical Expansion RARE DISEASES PORTFOLIO FY2023 H1 Revenue JPY 87.1B (+13.1% growth) FY 2023 H 1 R E V E N UE • TAKHZYRO continues its strong momentum driven by suc
Slide 31: PDT Portfolio Continues to Deliver Outstanding Growth
P L ASM A - D ER IVED T H ER AP IES PDT Portfolio Continues to Deliver Outstanding Growth PDT IMMUNOLOGY PORTFOLIO Immunoglobulin Albumin FY 2023 H 1 R E V E N UE FY23 H1 Revenue JPY 309.2B (+19.0% growth) FY23 H1 Revenue JPY 58.9B (+10.9% growth) (BN JPY) • Strong demand globally, especially in the
Slide 32: Oncology Growth Impacted by VELCADE Generics
ONC OL OG Y Oncology Growth Impacted by VELCADE Generics; Portfolio Excluding VELCADE Grew +6% at CER ONCOLOGY PORTFOLIO FY 2023 H 1 R E V E N UE • Takeda intends to initiate voluntary global withdrawal: confirmatory trial in (BN JPY) locally advanced or metastatic 1L EGFR Exon20 insertion+ NSCLC di
Slide 33: VYVANSE U.S. Loss of Exclusivity Impacting from August
NEU R OSC IENC E VYVANSE U.S. Loss of Exclusivity Impacting from August as Expected N EURO SCIENCE P O RTFOL IO FY2023 H1 Revenue JPY 226.3B (+0.7% growth) FY 2023 H 1 R E V E N UE (BN JPY) • Strong performance in April-August ahead of Loss of Exclusivity driven by expanding ADHD adult population an
Slide 34: Important Near-Term LCM Expansions Represent Significant Growth Opportunities
Important Near-Term LCM Expansions Represent Significant Growth Opportunities FY23 FY24 ENTYVIO maralixibat Filed SC CD (US) Target Filing ALGS, PFIC (Japan) GASTROINTESTINAL AND INFLAMMATION ALOFISEL Target Filing Perianal Fistulas (US)1 ICLUSIG Target Filing 1L Ph+ ALL (US) ONCOLOGY CABOMETYX Targ
Slide 35: Entyvio: Continuing Evidence Generation and Indication Expansion
Entyvio: Continuing Evidence Generation and Indication Expansion PHASE 3 PUBLISHED/PRESENTED FILED APPROVED ENTYVIO® ENTYVIO® ENTYVIO® IV, Pediatric (Global) IV, H2H vs. adalimumab (VARSITY)1 IV (Global) Ulcerative colitis ENTYVIO® SC (US, EU, JP) ENTYVIO® ENTYVIO® IV, Pediatric (Global) IV (Global)
Slide 36: TAK-279: Phase 2B Indicates Potential for Best-in-class Oral Psoriasis Treatment
TAK-279: Phase 2B Indicates Potential for Best-in-class Oral Treatment Option for Psoriasis Patients achieving PASI 75, 90 or 100 at Week 121 Summary 100% • Robust efficacy: 33% of patients on 30mg 90% PASI 75 PASI 90 PASI 100 % patients achieving PASI scores achieving clear skin at 12 weeks (PASI 1
Slide 37: Consolidated Development Pipeline by Phase
Consolidated Development Pipeline by Phase PHASE 1 (12 NMEs + 1 LCM) PHASE 2 (18 NMEs + 1 LCM) TAK-647 TAK-279 TAK-101 TAK-951 NASH Psoriasis Celiac Disease Nausea & vomiting GASTROINTESTINAL AND INFLAMMATION TAK-279 TAK-227 zamaglutenase1 Psoriatic Arthritis Celiac Disease Celiac Disease TAK-861 TA
Slide 38: Consolidated Development Pipeline by Phase
Consolidated Development Pipeline by Phase PHASE 3 (5 NMEs + 21 LCMs) FILED (3 NME + 18 LCMs) fazirsiran ENTYVIO® ALOFISEL® maralixibat ENTYVIO® VOCINTI® TAK-721 AATD Liver Disease Perianal Fistulas SC UC (US) Eosinophilic esophagitis Pediatric UC in CD (US)1 ALGS (JP) H. Pylori (CN) (US) GASTROINTE
Slide 39: Clinical Development Pipeline Changes in FY23
Clinical Development Pipeline Changes in FY23 New To Phase 1 New To Phase 2 New To Phase 3 New Regulatory Filings TAK-012 danavorexton ADYNOVATE® TAK-721 ENTYVIO® Acute myeloid Postanesthesia recombinant Factor VIII Eosinophilic esophagitis SC CD (US) leukemia recovery HemA (CN) (US) TAK-647 dazosti
Slide 40: Glossary of Abbreviations
Glossary of Abbreviations Regional Abbreviations: DSQ Dysphagia Symptom Questionnaire LGS Lennox-Gastaut syndrome PTCL-NOS peripheral T-cell lymphoma not otherwise specified CN: China; EU: Europe; JP: Japan; UK: United Kingdom; U.S.: EGFR epidermal growth factor receptor mCRC metastatic colorectal c
Slide 41: Financial Appendix
FINANCIAL APPENDIX Definition of Non-IFRS Measures Definition of Core Financial Measures, Constant Exchange Rate Change, Free Cash Flow, and U.S. Dollar Convenience Translations A-1 Definition of EBITDA/Adjusted EBITDA and Net Debt A-2 Reconciliations and Other Financial Information FY2023 H1 Report
Slide 42: Definition of Core Financial Measures, CER, Free Cash Flow
Definition of Core Financial Measures, Constant Exchange Rate Change, Free Cash Flow, and U.S. Dollar Convenience Translations Core Revenue represents revenue adjusted to exclude significant items unrelated to Takeda’s core operations. Core Operating Profit represents net profit adjusted to exclude
Slide 43: Definition of EBITDA/Adjusted EBITDA and Net Debt
Definition of EBITDA/Adjusted EBITDA and Net Debt We present EBITDA and Adjusted EBITDA because we believe that these measures are useful to investors as they are frequently used by securities analysts, investors and other interested parties in the evaluation of companies in our industry. We further
Slide 44: FY2023 H1 Reported Results with CER % Change
FY2023 H1 Reported Results with CER % Change vs. PY (Million USD, except EPS) (Billion JPY, except EPS) FY2022 H1 FY2023 H1 AER CER FY2023 H1 Convenience Amount of Change % CHANGE % CHANGE USD Translation Revenue 1,974.8 2,101.7 126.9 6.4% 1.4% 14,065 Cost of sales (598.3) (664.7) (66.4) (11.1)% (6.
Slide 45: FY2023 Q2 (Jul-Sep) Reported Results with CER % Change
FY2023 Q2 (Jul-Sep) Reported Results with CER % Change vs. PY (Million USD, except EPS) FY2022 Q2 FY2023 Q2 (Billion JPY, except EPS) AER CER FY2023 Q2 (Jul-Sep) (Jul-Sep) (Jul-Sep) Convenience Amount of Change % CHANGE % CHANGE USD Translation Revenue 1,002.3 1,043.1 40.8 4.1% (0.8)% 6,980 Cost of
Slide 46: FY2023 H1 Core Results with CER % Change
FY2023 H1 Core Results with CER % Change vs. PY (Million USD, except EPS) (Billion JPY, except EPS) FY2022 H1 FY2023 H1 AER CER FY2023 H1 Convenience Amount of Change % CHANGE % CHANGE USD Translation Revenue 1,974.8 2,101.7 126.9 6.4% 1.4% 14,065 Cost of sales (571.6) (664.8) (93.3) (16.3)% (10.9)%
Slide 47: FY2023 Q2 (Jul-Sep) Core Results with CER % Change
FY2023 Q2 (Jul-Sep) Core Results with CER % Change vs. PY (Million USD, except EPS) FY2022 Q2 FY2023 Q2 (Billion JPY, except EPS) AER CER FY2023 Q2 (Jul-Sep) (Jul-Sep) (Jul-Sep) Convenience Amount of Change % CHANGE % CHANGE USD Translation Revenue 1,002.3 1,043.1 40.8 4.1% (0.8)% 6,980 Cost of sale
Slide 48: FY2023 H1 Reconciliation from Reported to Core
FY2023 H1 Reconciliation from Reported to Core REPORTED TO CORE ADJUSTMENTS (Billion JPY, except EPS and number of shares) REPORTED Amortization of Impairment of Other CORE intangible intangible operating income/ Others assets assets expenses Revenue 2,101.7 2,101.7 Cost of sales (664.7) (0.1) (664.
Slide 49: FY2023 Q2 (Jul-Sep) Reconciliation from Reported to Core
FY2023 Q2 (Jul-Sep) Reconciliation from Reported to Core REPORTED TO CORE ADJUSTMENTS (Billion JPY, except EPS and number of shares) REPORTED Amortization of Impairment of Other CORE intangible intangible operating income/ Others assets assets expenses Revenue 1,043.1 1,043.1 Cost of sales (343.6) (
Slide 50: FY2022 H1 Reconciliation from Reported to Core
FY2022 H1 Reconciliation from Reported to Core REPORTED TO CORE ADJUSTMENTS (Billion JPY, except EPS and number of shares) REPORTED Amortization of Impairment of Other CORE intangible intangible operating income/ Others assets assets expenses Revenue 1,974.8 1,974.8 Cost of sales (598.3) 26.8 (571.6
Slide 51: FY2022 Q2 (Jul-Sep) Reconciliation from Reported to Core
FY2022 Q2 (Jul-Sep) Reconciliation from Reported to Core REPORTED TO CORE ADJUSTMENTS (Billion JPY, except EPS and number of shares) REPORTED Amortization of Impairment of Other CORE intangible intangible operating income/ Others assets assets expenses Revenue 1,002.3 1,002.3 Cost of sales (305.4) 1
Slide 52: FY2023 H1 Free Cash Flow
FY2023 H1 Free Cash Flow (Million USD) (Billion JPY) FY2022 H1 FY2023 H1 vs. PY FY2023 H1 Convenience USD Translation Net profit 166.8 41.4 (125.3) (75.2)% 277 Depreciation, amortization and impairment loss 362.1 480.9 118.8 3,218 Decrease (increase) in trade working capital (159.0) (200.7) (41.7) (
Slide 53: FY2023 H1 Net Debt to Adjusted EBITDA
FY2023 H1 Net Debt to Adjusted EBITDA NET DEBT/ADJUSTED EBITDA RATIO NET INCREASE (DECREASE) IN CASH FY2023 FY2022 FY2023 (Billion JPY) (Billion JPY) vs. PY H1 H1 H1 *1 Cash & cash equivalents and Level 1 debt investments 162.0 Net cash from operating activities 305.2 291.3 (13.9) (4.6)% Book value
Slide 54: FY2022 Net Debt to Adjusted EBITDA
FY2022 Net Debt to Adjusted EBITDA NET DEBT/ADJUSTED EBITDA RATIO NET INCREASE (DECREASE) IN CASH (Billion JPY) FY2022 (Billion JPY) FY2021 FY2022 vs. PY *1 Cash and cash equivalents 407.7 Net cash from operating activities 1,123.1 977.2 (145.9) (13.0)% Book value debt on consolidated statements of
Slide 55: FY2023 H1 Net Profit to Adjusted EBITDA Bridge
FY2023 H1 Net Profit to Adjusted EBITDA Bridge FY2022 FY2023 (Billion JPY) vs. PY H1 H1 Net profit 166.8 41.4 (125.3) (75.2)% Income tax expenses 53.3 (2.4) Depreciation and amortization 326.1 354.2 Interest expense, net 57.5 54.0 EBITDA 603.7 447.2 (156.5) (25.9)% Impairment losses 36.0 126.7 Other
Slide 56: FY2023 H1 Net Profit to Adjusted EBITDA LTM Bridge
FY2023 H1 Net Profit to Adjusted EBITDA LTM Bridge FY2022 FY2022 FY2023 FY2023 (Billion JPY) Full Year H1 H1 H1 LTM*1 (Apr - Mar) (Apr - Sep) (Apr - Sep) (Oct - Sep) Net profit 317.0 166.8 41.4 191.7 Income tax expenses 58.1 53.3 (2.4) 2.4 Depreciation and amortization 664.4 326.1 354.2 692.5 Intere
Slide 57: FY2023 H1 CAPEX, Depreciation and Amortization and Impairment Losses
FY2023 H1 CAPEX, Depreciation and Amortization and Impairment Losses FY2022 FY2023 FY2023 Revised Forecast (Billion JPY) vs. PY H1 H1 (October 26, 2023) Capital expenditures*1 139.0 339.3 200.3 144.1% 480.0 - 530.0*3 Tangible assets 71.4 83.8 12.4 17.3% Intangible assets 67.6 255.5 187.9 278.1% Depr
Slide 58: FY2023 Full Year Detailed Forecast
FY2023 Full Year Detailed Forecast FY2023 FY2023 vs. Original (BN JPY) Original Forecast Revised Forecast Reason for Variances Forecast (May 11, 2023) (October 26, 2023) Revenue 3,840.0 3,980.0 140.0 3.6 % Predominantly due to change in FX rate assumptions R&D expenses (643.0) (680.0) (37.0) (5.8)%
Slide 59: FY2023 Full Year Reconciliation from Reported to Core Operating Profit Forecast
FY2023 Full Year Reconciliation from Reported Operating Profit to Core Operating Profit Forecast REPORTED TO CORE ADJUSTMENTS Other (Billion JPY) REPORTED Amortization of Impairment of CORE operating intangible intangible Others income assets assets (expenses) Revenue 3,980.0 3,980.0 Cost of sales G
Slide 60: FY2023 Full Year FX Rates Assumptions and Currency Sensitivity
FY2023 Full Year FX Rates Assumptions and Currency Sensitivity Average Exchange Rates vs. JPY Impact of depreciation of yen from October 2023 to March 2024 (100 million JPY) Core FY2022 H1 FY2023 H1 FY2023 Operating Revenue Net Profit Operating Actual Actual Assumption Profit (IFRS) (IFRS) Profit (A
Slide 61: © 2023 Takeda Pharmaceutical Company Limited. All rights reserved.
© 2023 Takeda Pharmaceutical Company Limited. All rights reserved.
Takeda Pharmaceutical Company — Q2 2023 Earnings Presentation on 6ix